Tags

Type your tag names separated by a space and hit enter

Transdermal delivery of antisense compounds.
Adv Drug Deliv Rev. 2000 Oct 31; 44(1):51-7.AD

Abstract

Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local treatment of skin disease and for systemic delivery. The iontophoretic mode of delivery for phosphorothioate oligonucleotides across hairless mouse skin reveals the potential limitation in the delivery of sufficient oligonucleotide to provide for efficacy. A potential solution to this problem is the use of significantly more potent C-5 propyne base modifications in a phosphorothioate oligonucleotide. The combination of the iontophoretic delivery mode with potent oligonucleotides resulted in selective inhibition of the CYP3A2 gene expression in the rat liver. Alternatively, oligomers with neutral charge combined with passive modes of transdermal delivery may also be feasible and represent an even more broadly applicable technology. Future studies will focus on specific applications of local and systemic therapy of antisense oligonucleotide in animal models for the design of treatment regimens.

Authors+Show Affiliations

Department of Biological Systems Engineering, University of Nebraska, Lincoln, NE, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11035197

Citation

Brand, R M., and P L. Iversen. "Transdermal Delivery of Antisense Compounds." Advanced Drug Delivery Reviews, vol. 44, no. 1, 2000, pp. 51-7.
Brand RM, Iversen PL. Transdermal delivery of antisense compounds. Adv Drug Deliv Rev. 2000;44(1):51-7.
Brand, R. M., & Iversen, P. L. (2000). Transdermal delivery of antisense compounds. Advanced Drug Delivery Reviews, 44(1), 51-7.
Brand RM, Iversen PL. Transdermal Delivery of Antisense Compounds. Adv Drug Deliv Rev. 2000 Oct 31;44(1):51-7. PubMed PMID: 11035197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transdermal delivery of antisense compounds. AU - Brand,R M, AU - Iversen,P L, PY - 2000/10/18/pubmed PY - 2001/2/28/medline PY - 2000/10/18/entrez SP - 51 EP - 7 JF - Advanced drug delivery reviews JO - Adv Drug Deliv Rev VL - 44 IS - 1 N2 - Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local treatment of skin disease and for systemic delivery. The iontophoretic mode of delivery for phosphorothioate oligonucleotides across hairless mouse skin reveals the potential limitation in the delivery of sufficient oligonucleotide to provide for efficacy. A potential solution to this problem is the use of significantly more potent C-5 propyne base modifications in a phosphorothioate oligonucleotide. The combination of the iontophoretic delivery mode with potent oligonucleotides resulted in selective inhibition of the CYP3A2 gene expression in the rat liver. Alternatively, oligomers with neutral charge combined with passive modes of transdermal delivery may also be feasible and represent an even more broadly applicable technology. Future studies will focus on specific applications of local and systemic therapy of antisense oligonucleotide in animal models for the design of treatment regimens. SN - 0169-409X UR - https://www.unboundmedicine.com/medline/citation/11035197/Transdermal_delivery_of_antisense_compounds_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-409X(00)00083-1 DB - PRIME DP - Unbound Medicine ER -